[1] PONIKOWSKIP, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8): 891-975. [2] MARZETTI E, CALVANI R, TOSATO M, et al. Sarcopenia: an overview[J]. Aging Clin Exp Res, 2017, 29(1):11-17. [3] PONIKOWSKIP, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Rev Esp Cardiol, 2016, 69(12): 1167. [4] LONCAR G, SPRINGER J, ANKER M, et al. Cardiac cachexia:hic et nunc[J]. J Cachexia Sarcopenia Muscle, 2016, 7(3): 246-260. [5] CHEN L K, LIU L K, WOO J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia[J]. J Am Med Dir Assoc, 2014,15(2): 95-101. [6] BUTROUS H, HUMMEL S L. Heart failure in older adults[J]. Can J Cardiol, 2016, 32(9): 1140-1147. [7] SPRINGER J, SPRINGER J I, ANKER S D. Muscle wasting and sarcopenia in heart failure and beyond: update 2017[J]. ESC Heart Fail, 2017, 4(4): 492-498. [8] KAMIYA K, HAMAZAKI N, MATSUZAWA R, et al. Sarcopenia: prevalence and prognostic implications in elderly patients with cardiovascular disease[J]. JCSM Clin Rep, 2017,2(2): 1-13. [9] DENNISON E M, SAYER A A, COOPER C. Epidemiology of sarcopenia and insight into possible therapeutic targets[J]. Nat Rev Rheumatol, 2017, 13(6): 340-347. |